Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | POLA1 | P09884 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6568601 | 0.92 | KDM1A (0.41) | KDM1ACYP2C19KMT2AKDM4EJAK2 | |
| SCHEMBL9364462 | 0.92 | ADRA2A (0.43) | KDM1AADRA2AKMT2AKDM4EJAK2 | |
| SCHEMBL19126994 | 0.84 | KDM1A (0.36) | KDM1AKDM4EJAK2ALDH1A1HPGD | |
| SCHEMBL15897036 | 0.84 | BACE1 (0.37) | KDM1ADRD2DRD3 | |
| SCHEMBL3020640 | 0.84 | KDM1A (0.36) | KDM1AKDM4EALDH1A1 | |
| SCHEMBL8635505 | 0.84 | ALDH1A1 (0.41) | ADRA2ACYP2C19KMT2AKDM4EJAK2 | |
| Lithium Ion SCHEMBL3665004 | 0.81 | KDM1A (0.34) | KDM1A | |
| SCHEMBL3899441 | 0.81 | MEN1 (0.43) | KDM1AKMT2ASIGMAR1 | |
| SCHEMBL2777365 | 0.80 | GAA (0.34) | ALDH1A1CYP3A4 | |
| SCHEMBL3905338 | 0.78 | OPRM1 (0.33) | KDM1AKMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| US-6391915-B2 | ANTIULCER AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| US-20020006956-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| EP-0976720-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998052913-A2 | LEUKOTRIENE B4 ANTAGONISTS, IN PARTICULAR 3-OXA-TETRAHYDRONAPHTHALENE-LTB4 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-11-26 | — | — | WO | disclosed |
| US-4957914-A | ANTIDEPRESSANTS, ANXIOLYTICS, HYPOTENSIVE AGENTS | SYNTEX (U.S.A.) INC. (US) | 1990-09-18 | — | — | US | disclosed |
| US-4530919-A | A 1,2,3,4-tetrahydronaphthalene carboxylic acid | PFIZER INC. (US) | 1985-07-23 | — | — | US | disclosed |
| US-4374148-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1983-02-15 | — | — | US | disclosed |
| US-4305955-A | ORAL HYPOGLYCEMIC AGENTS, CHROMAN-4-CARBOXYLIC ACID OR THIOCHROMAN-4-CARBOXYLIC ACID | PFIZER INC. (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | KDM1A 3743/4885LMNA 701/4885ADRA2A 390/4885 |
| US-20020006956-A1 | Propanolamine derivatives | PNLIP, ADRB1, FABP2 | KDM1A 1758/4885LMNA 2259/4885ADRA2A 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.